ACE and acute myeloid leukemia: Exposition to angiotensin-converting enzyme (ACE) inhibitors was significantly higher in AML patients with AKI than in AML patients without AKI (n = 24, 36.1%, vs. n = 63, 19.1%, p = 0.003).